AHB-137
Sponsors
Ausper Biopharma Co., Ltd., AusperBio Therapeutics Inc.
Conditions
Chronic Hepatitis BHepatitis B, Chronic
Phase 2
Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).
Active, not recruitingNCT06550128
Start: 2024-07-10End: 2026-10-01Updated: 2026-05-07
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
Active, not recruitingNCT06829329
Start: 2024-12-13End: 2026-12-01Updated: 2026-05-07
A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
Active, not recruitingNCT06993480
Start: 2025-07-15End: 2027-02-09Updated: 2026-05-04
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
RecruitingNCT07069569
Start: 2025-06-08End: 2028-01-15Target: 200Updated: 2026-05-20
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
RecruitingNCT07137910
Start: 2025-09-04End: 2027-06-01Target: 60Updated: 2026-05-04
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
RecruitingNCT07370207
Start: 2026-03-06End: 2028-12-31Target: 84Updated: 2026-06-01
A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B
Not yet recruitingNCT07635186
Start: 2026-06-20End: 2028-06-20Target: 320Updated: 2026-06-09
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
Not yet recruitingNCT07654283
Start: 2026-06-17End: 2028-07-26Target: 70Updated: 2026-06-17